Interventions for latent autoimmune diabetes (LADA) in adults.
暂无分享,去创建一个
[1] L. Groop,et al. Worse glycaemic control in LADA patients than in those with type 2 diabetes, despite a longer time on insulin therapy , 2013, Diabetologia.
[2] S. Inzucchi. Clinical practice. Diagnosis of diabetes. , 2012, New England Journal of Medicine.
[3] M. Górska,et al. Latent autoimmune diabetes in adults in a population-based cohort of Polish patients with newly diagnosed diabetes mellitus , 2012, Archives of medical science : AMS.
[4] Maria Thunander,et al. Levels of C-peptide, body mass index and age, and their usefulness in classification of diabetes in relation to autoimmunity, in adults with newly diagnosed diabetes in Kronoberg, Sweden , 2012, European journal of endocrinology.
[5] Xiang Yan,et al. Protective effects of 1‐α‐hydroxyvitamin D3 on residual β‐cell function in patients with adult‐onset latent autoimmune diabetes (LADA) , 2009, Diabetes/metabolism research and reviews.
[6] J. Ioannidis,et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, BMJ : British Medical Journal.
[7] T. Vos,et al. Cost-Effectiveness of Interventions to Promote Physical Activity: A Modelling Study , 2009, PLoS medicine.
[8] Å. Lernmark,et al. GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes , 2009, Diabetologia.
[9] Richard S. Rosenthal,et al. Latent autoimmune diabetes of adulthood (LADA): An often misdiagnosed type of diabetes mellitus , 2009, Journal of the American Academy of Nurse Practitioners.
[10] I. Hilldrup,et al. Latent autoimmune diabetes in adults (LADA) in South Wales: incidence and characterization , 2008, Diabetic medicine : a journal of the British Diabetic Association.
[11] H. Kolb,et al. Diabetes classification: grey zones, sound and smoke: Action LADA 1 , 2008, Diabetes/metabolism research and reviews.
[12] De-Xian Zhang,et al. [Effect of Tangyikang in improving the function of pancreatic islet beta cells in patients with latent autoimmune diabetes mellitus in adults]. , 2008, Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine.
[13] A. Clark,et al. Autoimmune diabetes in adults: lessons from the UKPDS , 2008, Diabetic medicine : a journal of the British Diabetic Association.
[14] I. Takei,et al. Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. , 2008, The Journal of clinical endocrinology and metabolism.
[15] H. Tian,et al. Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial , 2008, The Lancet.
[16] B. Richter,et al. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. , 2008, The Cochrane database of systematic reviews.
[17] H. Makino,et al. Anti-thyroid peroxidase antibody, IA-2 antibody, and fasting C-peptide levels predict beta cell failure in patients with latent autoimmune diabetes in adults (LADA)--a 5-year follow-up of the Ehime study. , 2008, Diabetes research and clinical practice.
[18] Jonathan A C Sterne,et al. Investigating and Dealing with Publication and Other Biases , 2008 .
[19] R. Heine,et al. The islet autoantibody titres: their clinical relevance in latent autoimmune diabetes in adults (LADA) and the classification of diabetes mellitus , 2008, Diabetic medicine : a journal of the British Diabetic Association.
[21] P. Bingley,et al. GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77 , 2007, Diabetologia.
[22] C. Clar,et al. Rosiglitazone for type 2 diabetes mellitus. , 2007, The Medical letter on drugs and therapeutics.
[23] J. Lau,et al. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. , 2007, JAMA.
[24] Å. Lernmark,et al. GAD65 autoantibody epitopes in adult patients with latent autoimmune diabetes following GAD65 vaccination , 2007, Diabetic medicine : a journal of the British Diabetic Association.
[25] I. Cohen,et al. Treatment of new‐onset type 1 diabetes with peptide DiaPep277® is safe and associated with preserved beta‐cell function: extension of a randomized, double‐blind, phase II trial , 2007, Diabetes/metabolism research and reviews.
[26] T. Battelino,et al. Effect of heat shock protein peptide DiaPep277 on ß‐cell function in paediatric and adult patients with recent‐onset diabetes mellitus type 1: two prospective, randomized, double‐blind phase II trials , 2007 .
[27] P. Royle,et al. Meglitinide analogues for type 2 diabetes mellitus. , 2007, The Cochrane database of systematic reviews.
[28] Alejandro R. Jadad,et al. Randomized controlled trials , 2007 .
[29] A. Sala,et al. Detección de diabetes tipo LADA en pacientes diabéticos con exceso ponderal. ¿Es adecuado el tratamiento con metformina? , 2007 .
[30] S. Purisch,et al. Latent autoimmune diabetes in adults (LADA): usefulness of anti-GAD antibody titers and benefit of early insulinization. , 2007, Arquivos brasileiros de endocrinologia e metabologia.
[31] C. Clar,et al. Pioglitazone for type 2 diabetes mellitus. , 2006, The Cochrane database of systematic reviews.
[32] P. Lucassen,et al. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. , 2006, The Cochrane database of systematic reviews.
[33] I. Olkin,et al. The case of the misleading funnel plot , 2006, BMJ : British Medical Journal.
[34] R. Naik,et al. Latent autoimmune diabetes in adults. , 2006, The Journal of clinical endocrinology and metabolism.
[35] P. Pozzilli,et al. Clinical review: Type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow. , 2006, The Journal of clinical endocrinology and metabolism.
[36] E. Chantelau. The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin. , 2006, Diabetes care.
[37] A. Gottsäter,et al. Latent autoimmune diabetes in adults: definition, prevalence, beta-cell function, and treatment. , 2005, Diabetes.
[38] E. Gale. Latent autoimmune diabetes in adults: a guide for the perplexed , 2005, Diabetologia.
[39] T. Heise,et al. The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic study. , 2005, Diabetes care.
[40] F. Nicoletti,et al. Lack of effect of intermittently administered sodium fusidate in patients with newly diagnosed type 1 diabetes mellitus: the FUSIDM trial , 2005, Diabetologia.
[41] Å. Lernmark,et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. , 2005, Journal of diabetes and its complications.
[42] A. Mayorov,et al. Influence of insulin treatment on insulin sensitivity in insulin requiring type 2 diabetes patients. , 2005, Diabetes research and clinical practice.
[43] 光生 松本,et al. 抗GAD抗体, ICA, IA-2抗体陽性で, 少量のインスリン治療で内因性インスリン分泌が保持されている緩徐進行1型糖尿病の1例 , 2005 .
[44] N. Emanuele,et al. Latent autoimmune diabetes of adulthood , 2005, Postgraduate medicine.
[45] Xiang Yan,et al. Rosiglitazone combined with insulin preserves islet β cell function in adult‐onset latent autoimmune diabetes (LADA) , 2005, Diabetes/metabolism research and reviews.
[46] R. Holman,et al. Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70) , 2005, Diabetologia.
[47] B. Zinman,et al. Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. , 2004, Diabetes.
[48] P. Raskin,et al. Oral Insulin Therapy to Prevent Progression of Immune‐Mediated (Type 1) Diabetes , 2004, Annals of the New York Academy of Sciences.
[49] F. Ovalle,et al. Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes. , 2004, Diabetes care.
[50] Zhenjie Liu,et al. [Study on improvement of islet beta cell function in patients with latent autoimmune diabetes mellitus in adults by integrative Chinese and Western medicine]. , 2004, Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine.
[51] J. Rasenack,et al. [Autoantibodies against islet cell antigens and type 1 diabetes after treatment with interferon-alpha]. , 2004, Deutsche medizinische Wochenschrift.
[52] B. Boehm,et al. Complete long-term recovery of beta-cell function in autoimmune type 1 diabetes after insulin treatment. , 2004, Diabetes care.
[53] I. Takei,et al. Multicenter Prevention Trial of Slowly Progressive Type 1 Diabetes with Small Dose of Insulin (the Tokyo Study) , 2003, Annals of the New York Academy of Sciences.
[54] A. Chacra,et al. Non-obese adult onset diabetes with oral hypoglycemic agent failure: islet cell autoantibodies or reversible beta cell refractoriness? , 2003, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[55] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[56] R. Naik,et al. Latent Autoimmune Diabetes in Adults (LADA) , 2003, Reviews in Endocrine and Metabolic Disorders.
[57] G. Sundkvist,et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. , 2003, Diabetes care.
[58] A. Hattersley,et al. Etiological investigation of diabetes in young adults presenting with apparent type 2 diabetes. , 2003, Diabetes care.
[59] P. Bingley,et al. Diabetes Antibody Standardization Program: first assay proficiency evaluation. , 2003, Diabetes.
[60] A. Pugliese. Peptide-based treatment for autoimmune diseases: learning how to handle a double-edged sword. , 2003, The Journal of clinical investigation.
[61] M. Steffes,et al. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. , 2003, Diabetes care.
[62] S. Thompson,et al. Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.
[63] H. Onuma,et al. Clinical, autoimmune, and genetic characteristics of adult-onset diabetic patients with GAD autoantibodies in Japan (Ehime Study). , 2002, Diabetes care.
[64] J. Palmer. Beta Cell Rest and Recovery—Does It Bring Patients with Latent Autoimmune Diabetes in Adults to Euglycemia? , 2002, Annals of the New York Academy of Sciences.
[65] I. Takei,et al. Insulin Intervention to Preserve β Cells in Slowly Progressive Insulin‐Dependent (Type 1) Diabetes Mellitus a , 2002, Annals of the New York Academy of Sciences.
[66] P. Pozzilli,et al. Thiazolidinediones for the prevention of diabetes in the non‐obese diabetic (NOD) mouse: implications for human type 1 diabetes , 2002, Diabetes/metabolism research and reviews.
[67] A. de Leiva,et al. Slowly Progressing Type 1 Diabetes: Persistence of Islet Cell Autoantibodies is Related to Glibenclamide Treatment , 2002, Autoimmunity.
[68] D. Altman,et al. Systematic reviews in health care : meta-analysis in context , 2001 .
[69] P. Pozzilli,et al. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention. , 2001, Diabetes care.
[70] W. Scherbaum,et al. Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA) , 2001, Diabetologia.
[71] Steff Lewis,et al. Forest plots: trying to see the wood and the trees , 2001, BMJ : British Medical Journal.
[72] C. Boitard,et al. Oral insulin administration and residual (β-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial , 2000, The Lancet.
[73] A. T. N. Group,et al. No effect of oral insulin on residual beta-cell function in recent-onset Type I diabetes (the IMDIAB VII) , 2000, Diabetologia.
[74] R. Casamitjana,et al. Effects of nicotinamide and intravenous insulin therapy in newly diagnosed type 1 diabetes. , 2000, Diabetes care.
[75] I. Olkin,et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement , 1999, The Lancet.
[76] L. Groop,et al. The role of sulphonylurea in combination therapy assessed in a trial of sulphonylurea withdrawal , 1999, Diabetic medicine : a journal of the British Diabetic Association.
[77] Å. Lernmark,et al. Islet cell and glutamic acid decarboxylase antibodies present at diagnosis of diabetes predict the need for insulin treatment. A cohort study in young adults whose disease was initially labeled as type 2 or unclassifiable diabetes. , 1999, Diabetes care.
[78] S. Nagataki,et al. The preliminary report from the nation-wide prevention study for type 1 diabetes initially diagnosed as type 2 in Japan. , 1998, Diabetes/metabolism reviews.
[79] R. Holman,et al. UKPDS 26: sulphonylurea failure in non‐insulin‐dependent diabetic patients over six years , 1998, Diabetic medicine : a journal of the British Diabetic Association.
[80] R. Holman,et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes , 1997, The Lancet.
[81] A. Romiti,et al. Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study) , 1997, European journal of endocrinology.
[82] T. Linn,et al. Intensive therapy in adult insulin-dependent diabetes mellitus is associated with improved insulin sensitivity and reserve: a randomized, controlled, prospective study over 5 years in newly diagnosed patients. , 1996, Metabolism: clinical and experimental.
[83] C. Berne,et al. Diazoxide Treatment at Onset Preserves Residual Insulin Secretion in Adults with Autoimmune Diabetes , 1996, Diabetes.
[84] K. Kosaka,et al. Small Doses of Subcutaneous Insulin as a Strategy for Preventing Slowly Progressive β-Cell Failure in Islet Cell Antibody—Positive Patients With Clinical Features of NIDDM , 1996, Diabetes.
[85] M. Ravnik-Oblak,et al. Insulin versus a combination of insulin and sulfonylurea in the treatment of NIDDM patients with secondary oral failure. , 1995, Diabetes research and clinical practice.
[86] R. Casamitjana,et al. Effects of a short prednisone regime at clinical onset of type 1 diabetes. , 1993, Diabetes research and clinical practice.
[87] L. Groop,et al. Antibodies to Glutamic Acid Decarboxylase Reveal Latent Autoimmune Diabetes Mellitus in Adults With a Non—Insulin-Dependent Onset of Disease , 1993, Diabetes.
[88] S. Martin,et al. Follow-up of cyclosporin A treatment in Type 1 (insulin-dependent) diabetes mellitus: lack of long-term effects , 1991, Diabetologia.
[89] A. Secchi,et al. Prednisone administration in recent onset type I diabetes. , 1990, Journal of autoimmunity.
[90] Jacob Cohen. A Coefficient of Agreement for Nominal Scales , 1960 .
[91] S. Brophy,et al. Experience of the introduction of routine antibody testing in primary care and of running a trial for latent autoimmune diabetes in adults (LADA). , 2011, Diabetes research and clinical practice.
[92] Zhiguang Zhou,et al. Rosiglitazone preserves islet beta-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study. , 2009, Diabetes research and clinical practice.
[93] G. Schernthaner,et al. Progress in the characterization of slowly progressive autoimmune diabetes in adult patients (LADA or type 1.5 diabetes). , 2001, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[94] R. Leslie. Intervention in patients with Type I diabetes masquerading as Type II diabetes : Prevention of insulin-dependent diabetes , 1996 .
[95] G. Bauer. Islets of Langerhans , 1983 .
[96] Sze Py. L-Glutamate decarboxylase. , 1979, Advances in experimental medicine and biology.
[97] V. Lotter,et al. Follow-Up Studies , 1978 .
[98] C. Petersson,et al. treatment: a 3-year follow-up , 2022 .
[99] R. Segurado,et al. A Randomized Controlled Trial , 2022 .